1-12 of 12
Roberto Salgado
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy

Miguel Martín, Rachel Yoder, Roberto Salgado, María del Monte-Millán, Enrique L. Álvarez, Isabel Echavarría, Joshua M. Staley, Anne P. O'Dea, Lauren E. Nye, Shane R. Stecklein, Coralia Bueno, Yolanda Jerez, María Cebollero, Oscar Bueno, José Ángel García Saenz, Fernando Moreno, Uriel Bohn, Henry Gómez, Tatiana Massarrah, Qamar J. Khan, Andrew K. Godwin, Sara López-Tarruella, Priyanka Sharma
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2160–2169.
https://doi.org/10.1158/1078-0432.CCR-24-0106
Published: 15 May 2024
View article titled, Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Open the PDF for Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

Holly Tovey, Orsolya Sipos, Joel S. Parker, Katherine A. Hoadley, Jelmar Quist, Sarah Kernaghan, Lucy Kilburn, Roberto Salgado, Sherene Loi, Richard D. Kennedy, Ioannis Roxanis, Patrycja Gazinska, Sarah E. Pinder, Judith Bliss, Charles M. Perou, Syed Haider, Anita Grigoriadis, Andrew Tutt, Maggie Chon U. Cheang
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3691–3705.
https://doi.org/10.1158/1078-0432.CCR-23-0370
Published: 15 September 2023
View article titled, Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
Open the PDF for Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727) in another window
Includes: Supplementary data
Journal Articles

Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy–Resistant Early Breast Cancers

Patrycja Gazinska, Charlotte Milton, Jacopo Iacovacci, Joseph Ward, Richard Buus, Thanussuyah Alaguthurai, Rosalind Graham, Ayse Akarca, Esther Lips, Kalnisha Naidoo, Jelle Wesseling, Teresa Marafioti, Maggie Cheang, Cheryl Gillett, Yin Wu, Aadil Khan, Alan Melcher, Roberto Salgado, Mitch Dowsett, Andrew Tutt, Ioannis Roxanis, Syed Haider, Sheeba Irshad
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4494–4508.
https://doi.org/10.1158/1078-0432.CCR-22-0543
Published: 14 October 2022
View article titled, Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy–Resistant Early Breast Cancers
Open the PDF for Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy–Resistant Early Breast Cancers in another window
Includes: Supplementary data
Journal Articles

What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as Sweet

Roberto Salgado, Sherene Loi
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2728–2729.
https://doi.org/10.1158/1078-0432.CCR-22-0783
Published: 01 July 2022
View article titled, What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as Sweet
Open the PDF for What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as Sweet in another window
Journal Articles

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial

David Venet, Mattia Rediti, Marion Maetens, Debora Fumagalli, David N. Brown, Samira Majjaj, Roberto Salgado, Lajos Pusztai, Nadia Harbeck, Sarra El-Abed, Yingbo Wang, Cristina Saura, Henry Gomez, Vladimir Fedorovich Semiglazov, Evandro de Azambuja, Jens Huober, Paolo Nuciforo, Serena Di Cosimo, Martine Piccart, Sherene Loi, Françoise Rothé, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5607–5618.
https://doi.org/10.1158/1078-0432.CCR-21-1317
Published: 15 October 2021
View article titled, Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
Open the PDF for Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)

Priyanka Sharma, Bruce F. Kimler, Anne O'Dea, Lauren Nye, Yen Y. Wang, Rachel Yoder, Joshua M. Staley, Lindsey Prochaska, Jamie Wagner, Amanda L. Amin, Kelsey Larson, Christa Balanoff, Manana Elia, Gregory Crane, Sheshadri Madhusudhana, Marc Hoffmann, Maureen Sheehan, Roberto Rodriguez, Karissa Finke, Rajvi Shah, Deepti Satelli, Anuj Shrestha, Larry Beck, Richard McKittrick, Robert Pluenneke, Vinay Raja, Venkatadri Beeki, Larry Corum, Jaimie Heldstab, Stephanie LaFaver, Micki Prager, Milind Phadnis, Dinesh Pal Mudaranthakam, Roy A. Jensen, Andrew K. Godwin, Roberto Salgado, Kathan Mehta, Qamar Khan
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (4): 975–982.
https://doi.org/10.1158/1078-0432.CCR-20-3646
Published: 15 February 2021
View article titled, Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
Open the PDF for Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP) in another window
Includes: Supplementary data
Journal Articles

Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer

François Richard, Samira Majjaj, David Venet, Françoise Rothé, Julien Pingitore, Bram Boeckx, Caterina Marchio, Florian Clatot, François Bertucci, Odette Mariani, Christine Galant, Gert van den Eynden, Roberto Salgado, Elia Biganzoli, Diether Lambrechts, Anne Vincent-Salomon, Giancarlo Pruneri, Denis Larsimont, Christos Sotiriou, Christine Desmedt
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6254–6265.
https://doi.org/10.1158/1078-0432.CCR-20-2268
Published: 01 December 2020
View article titled, Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer
Open the PDF for Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

Margaret L. Axelrod, Mellissa J. Nixon, Paula I. Gonzalez-Ericsson, Riley E. Bergman, Mark A. Pilkinton, Wyatt J. McDonnell, Violeta Sanchez, Susan R. Opalenik, Sherene Loi, Jing Zhou, Sean Mackay, Brent N. Rexer, Vandana G. Abramson, Valerie M. Jansen, Simon Mallal, Joshua Donaldson, Sara M. Tolaney, Ian E. Krop, Ana C. Garrido-Castro, Jonathan D. Marotti, Kevin Shee, Todd W. Miller, Melinda E. Sanders, Ingrid A. Mayer, Roberto Salgado, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (21): 5668–5681.
https://doi.org/10.1158/1078-0432.CCR-19-3685
Published: 02 November 2020
View article titled, Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Open the PDF for Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, Susan Combs, David L. Rimm, Jennifer M. Giltnane, Monica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Rebecca S. Cook, Mark A. Pilkinton, Simon A. Mallal, Kai Wang, Vincent A. Miller, Phil J. Stephens, Roman Yelensky, Franco D. Doimi, Henry Gómez, Sergey V. Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1437.
https://doi.org/10.1158/1078-0432.CCR-18-4264
Published: 15 February 2019
View article titled, Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Open the PDF for Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors in another window
Journal Articles

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Hope S. Rugo, Jean-Pierre Delord, Seock-Ah Im, Patrick A. Ott, Sarina A. Piha-Paul, Philippe L. Bedard, Jasgit Sachdev, Christophe Le Tourneau, Emilie M.J. van Brummelen, Andrea Varga, Roberto Salgado, Sherene Loi, Sanatan Saraf, Dina Pietrangelo, Vassiliki Karantza, Antoinette R. Tan
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2804–2811.
https://doi.org/10.1158/1078-0432.CCR-17-3452
Published: 14 June 2018
View article titled, Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Open the PDF for Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, Susan Combs, David L. Rimm, Jennifer M. Giltnane, Monica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Rebecca S. Cook, Mark A. Pilkinton, Simon A. Mallal, Kai Wang, Vincent A. Miller, Phil J. Stephens, Roman Yelensky, Franco D. Doimi, Henry Gómez, Sergey V. Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1499–1509.
https://doi.org/10.1158/1078-0432.CCR-15-1125
Published: 14 March 2016
View article titled, RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Open the PDF for RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors in another window
Includes: Supplementary data
Journal Articles

Increased Serum Interleukin-8 in Patients with Early and Metastatic Breast Cancer Correlates with Early Dissemination and Survival

Ina H. Benoy, Roberto Salgado, Peter Van Dam, Katrien Geboers, Eric Van Marck, Simon Scharpé, Peter B. Vermeulen, Luc Y. Dirix
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (21): 7157–7162.
https://doi.org/10.1158/1078-0432.CCR-04-0812
Published: 08 November 2004
View article titled, Increased Serum Interleukin-8 in Patients with Early and Metastatic Breast Cancer Correlates with Early Dissemination and Survival
Open the PDF for Increased Serum Interleukin-8 in Patients with Early and Metastatic Breast Cancer Correlates with Early Dissemination and Survival in another window